logo
logo

NanoSurface Biomedical Awarded $1.9M in Funding from NIH

Mar 03, 2020•over 5 years ago

Amount Raised

$1 Million

Round Type

seed

Seattle

Description

NanoSurface Biomedical received $1.9 million in new funding in 2019 from the National Institutes of Health (NIH) to support accelerated development of NanoSurface’s innovative human induced pluripotent stem cell (iPSC)-based platforms for drug discovery and safety screening. This funding announcement brings the total non-dilutive Small Business Innovative Research (SBIR) funding NanoSurface has received from the NIH to $3.1 million. Under the terms of the funding awards, NanoSurface will receive an additional $1.5 million upon successful completion of scientific milestones.

Company Information

Company

Nano Surface Biomedical

Location

Seattle, Washington, United States

About

NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops stem cell-based assay technologies to accelerate drug development. NanoSurface’s structurally matured cardiac tissue models, assay instruments, and discovery services leverage human stem cell technology to help pharmaceutical companies predictively assess the safety and efficacy of candidate drugs early during preclinical development. NanoSurface’s mission is to help bring life-saving medicines to market in less time and at lower cost. To learn more, visit www.nanosurfacebio.com.

Related People